Post PCI Antiplatelet Strategy Selection Tool

Post PCI Antiplatelet Strategy Selection Tool Explanation and Clinical Context This tool is designed as a structured aid for clinicians who individualize antiplatelet strategy after percutaneous coronary intervention in the setting of acute coronary syndromes. Current professional guidelines emphasize that duration and intensity of antiplatelet therapy after PCI are determined by a balance between ischemic risk related to the coronary event and stent characteristics and bleeding risk related to patient factors and concomitant therapies. In patients with acute coronary syndrome treated with contemporary drug eluting stents a standard approach is a course of dual antiplatelet therapy with aspirin plus a P2Y12 receptor inhibitor for around twelve months when bleeding risk is not excessive.

Patients with high bleeding risk or those who require chronic oral anticoagulation often benefit from a shorter period of combined therapy followed by single antiplatelet therapy in addition to anticoagulation. Very early after PCI premature interruption of antiplatelet therapy increases the risk of stent thrombosis therefore any change in treatment during this phase should be reserved for situations where bleeding or other urgent indications clearly outweigh ischemic hazard. The recommendations for extended treatment beyond twelve months focus on patients with high ischemic risk such as those with recurrent events extensive coronary artery disease or complex PCI in whom continuation of intensified antithrombotic therapy may reduce recurrent myocardial infarction at the expense of higher bleeding risk.

Decisions in this phase require thoughtful review of guideline statements comprehensive assessment of bleeding and ischemic risk scores and shared decision making with the patient. This calculator does not replace guideline documents or clinical judgement. It does not choose specific agents or doses and it does not incorporate all contraindications drug interactions or patient preferences.

Instead it organizes key elements such as time from PCI bleeding risk ischemic risk and need for chronic oral anticoagulation and returns a narrative reminder of guideline consistent principles that can be brought to the bedside or catheterization laboratory discussion. Reference Rao SV et al. Guideline for the management of patients with acute coronary syndromes.

Journal of the American College of Cardiology. Two thousand twenty five. American Heart Association and American College of Cardiology joint guideline document.

Valgimigli M et al. Dual antiplatelet therapy after percutaneous coronary intervention in acute coronary syndromes. Journal of the American College of Cardiology and related professional society documents on duration of antiplatelet therapy.

Bhatt DL et al. Role of long term antithrombotic therapy after myocardial infarction and percutaneous coronary intervention. Contemporary evidence from randomized trials and guideline summaries.